Imunon, Inc.

IMNN

Healthcare|Biotechnology|US

$0.84

-0.06 (-6.16%)

DCF Value

$3.07

Tangible Book / Share

$0.80

Cash / Share

$1.31

About

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

Stock Price

-78.7%(1Y)

-21.0%

-47.5%

-68.9%

YTD

-77.8%

-77.5%

-94.4%

-99.6%

Pipeline Summary

17 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Active: 1Completed: 8Terminated: 1Withdrawn: 3Unknown: 2Recruiting: 2

Active Trials (3)

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT03393884Epithelial Ovarian Cancer

Phase 1Phase 2Active

Enrollment: 130 participants

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981Ovarian Cancer

Phase 1Phase 2Recruiting

Enrollment: 30 participants

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025Epithelial Ovarian Cancer

Phase 3Recruiting

Enrollment: 500 participants

Key Facts

Market Cap$4.7M

Employees20 (-20% YoY)

CEOStacy R. Lindborg

IPO DateMar 1, 1999

Beta2.08

52-Week Range$0.81 – $4.38

Avg Volume139,062

ExchangeNASDAQ

Websiteimunon.com

Ownership

Float85.7%

Shares Outstanding5.6M

Recent Insider Trades

Tardugno Michael HAWARD

Oct 23, 20266,821 shares @ $1.24

Lindborg StacyAWARD

Oct 23, 20262,603 shares @ $1.24

Faller Douglas VincentAWARD

Oct 23, 202626,741 shares @ $1.24

Faller Douglas VincentAWARD

Oct 23, 20261,092 shares @ $1.24

Tardugno Michael HAWARD

Oct 9, 20267,800 shares @ $1.08

Peers

AEONAEON Biopharma, Inc.

$8.8M

BOLTBolt Biotherapeutics, Inc.

$12.6M

CINGCingulate Inc.

$61.9M

CLRBCellectar Biosciences, Inc.

$11.8M

COCPCocrystal Pharma, Inc.

$20.0M

DWTXDogwood Therapeutics, Inc.

$48.9M

EVGNEvogene Ltd.

$2.3M

MRKRMarker Therapeutics, Inc.

$14.9M

Recent News

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

Nov 6, 2026 · globenewswire.com

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

Nov 2, 2026 · globenewswire.com

IMUNON Announces Strategic Sale of ThermoDox®

Oct 21, 2026 · globenewswire.com

IMUNON to Participate in Upcoming Investor Conferences

Oct 8, 2026 · globenewswire.com

IMUNON Converts $1.2 Million of Debt-to-Equity

Sep 29, 2026 · globenewswire.com

Data last updated: Nov 9, 2026, 04:15 AM